Suppr超能文献

医学中心的檀香山肝病聚集区:其谜团与挑战。

The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges.

作者信息

Teschke Rolf, Eickhoff Axel

机构信息

Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, Leimenstrasse 20, D-63450 Hanau, Germany.

出版信息

Int J Mol Sci. 2016 Mar 31;17(4):476. doi: 10.3390/ijms17040476.

Abstract

In 2013, physicians at the Honolulu Queen's Medical Center (QMC) noticed that seven liver disease patients reported the use of OxyELITE Pro (OEP), a widely consumed dietary supplement (DS). Assuming a temporal association between OEP use and disease, they argued that OEP was the cause of this mysterious cluster. Subsequent reexamination, however, has revealed that this QMC cohort is heterogeneous and not a cluster with a single agent causing a single disease. It is heterogeneous because patients used multiple DS's and drugs and because patients appeared to have suffered from multiple liver diseases: liver cirrhosis, liver failure by acetaminophen, hepatotoxicity by non-steroidal antiinflammatory drugs (NSAIDs), resolving acute viral hepatitis by hepatitis B virus (HBV), herpes simplex virus (HSV), and varicella zoster virus (VZV), and suspected hepatitis E virus (HEV). Failing to exclude these confounders and to consider more viable diagnoses, the QMC physicians may have missed specific treatment options in some of their patients. The QMC physicians unjustifiably upgraded their Roussel Uclaf Causality Assessment Method (RUCAM) causality scores so that all patients would appear to be "probable" for OEP. However, subsequent RUCAM reassessments by our group demonstrated a lack of causality for OEP in the evaluated QMC cases. The QMC's questionable approaches explain the extraordinary accumulation of suspected OEP cases at the QMC in Hawaii as single place, whereas similar cohorts were not published by any larger US liver center, substantiating that the problem is with the QMC. In this review article, we present and discuss new case data and critically evaluate upcoming developments of problematic regulatory assessments by the US Centers for Disease Control and Prevention (CDC), the Hawaii Department of Health (HDOH), and the Food and Drug Administration (FDA), as based on invalid QMC conclusions, clarifying now also basic facts and facilitating constructive discussions.

摘要

2013年,檀香山女王医疗中心(QMC)的医生注意到,有7名肝病患者报告使用了OxyELITE Pro(OEP),这是一种广泛消费的膳食补充剂(DS)。鉴于OEP使用与疾病之间存在时间关联,他们认为OEP是这一神秘病例群的病因。然而,随后的重新检查发现,这个QMC队列具有异质性,并非由单一因素导致单一疾病的病例群。它具有异质性是因为患者使用了多种膳食补充剂和药物,还因为患者似乎患有多种肝病:肝硬化、对乙酰氨基酚所致肝衰竭、非甾体抗炎药(NSAIDs)所致肝毒性、由乙型肝炎病毒(HBV)、单纯疱疹病毒(HSV)和水痘带状疱疹病毒(VZV)引起的急性病毒性肝炎已痊愈,以及疑似戊型肝炎病毒(HEV)感染。由于未能排除这些混杂因素并考虑更可行的诊断,QMC的医生可能在一些患者中错过了特定的治疗选择。QMC的医生不合理地提高了他们的鲁塞尔·优克福因果关系评估方法(RUCAM)因果关系评分,以便所有患者似乎都“可能”与OEP有关。然而,我们团队随后对RUCAM的重新评估表明,在评估的QMC病例中,OEP与疾病不存在因果关系。QMC的可疑方法解释了夏威夷QMC作为单一地点出现大量疑似OEP病例的异常情况,而美国任何更大的肝脏中心都未公布类似队列,这证实问题出在QMC。在这篇综述文章中,我们展示并讨论新的病例数据,并严格评估美国疾病控制与预防中心(CDC)、夏威夷卫生部(HDOH)和食品药品监督管理局(FDA)基于无效的QMC结论进行的有问题的监管评估的未来发展,同时阐明基本事实并促进建设性的讨论。

相似文献

1
The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges.
Int J Mol Sci. 2016 Mar 31;17(4):476. doi: 10.3390/ijms17040476.
3
Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ - Hawaii, 2013.
Drug Test Anal. 2016 Mar-Apr;8(3-4):319-27. doi: 10.1002/dta.1894. Epub 2015 Nov 2.
6
Drug-induced liver injury.
Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016.
7
Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM).
Clin Toxicol (Phila). 2011 Jan;49(1):34-9. doi: 10.3109/15563650.2010.537662. Epub 2010 Nov 29.
9

引用本文的文献

4
Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases.
J Clin Transl Hepatol. 2020 Jun 28;8(2):200-214. doi: 10.14218/JCTH.2020.00009. Epub 2020 Apr 24.
6
Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury?
JGH Open. 2018 Jun 6;2(4):152-157. doi: 10.1002/jgh3.12057. eCollection 2018 Aug.
8
Drug induced liver injury with analysis of alternative causes as confounding variables.
Br J Clin Pharmacol. 2018 Jul;84(7):1467-1477. doi: 10.1111/bcp.13593. Epub 2018 May 14.
9
Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury.
J Clin Transl Hepatol. 2018 Mar 28;6(1):57-68. doi: 10.14218/JCTH.2017.00033. Epub 2017 Oct 27.

本文引用的文献

1
RUCAM in Drug and Herb Induced Liver Injury: The Update.
Int J Mol Sci. 2015 Dec 24;17(1):14. doi: 10.3390/ijms17010014.
4
Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ - Hawaii, 2013.
Drug Test Anal. 2016 Mar-Apr;8(3-4):319-27. doi: 10.1002/dta.1894. Epub 2015 Nov 2.
6
Disseminated Herpes Simplex Virus with Fulminant Hepatitis.
Case Reports Hepatol. 2015;2015:463825. doi: 10.1155/2015/463825. Epub 2015 Jul 28.
7
How to Diagnose and Exclude Drug-Induced Liver Injury.
Dig Dis. 2015;33(4):472-6. doi: 10.1159/000374091. Epub 2015 Jul 6.
8
Herbal hepatotoxicity: current status, examples, and challenges.
Expert Opin Drug Metab Toxicol. 2015;11(10):1551-65. doi: 10.1517/17425255.2015.1064110. Epub 2015 Jul 6.
9
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps.
Front Pharmacol. 2015 Apr 23;6:72. doi: 10.3389/fphar.2015.00072. eCollection 2015.
10
Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment.
Gastroenterology. 2015 Jun;148(7):1271-3. doi: 10.1053/j.gastro.2015.04.027. Epub 2015 Apr 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验